Details for Patent: 12,097,187

Which drugs does patent 12,097,187 protect, and when does it expire?

Patent 12,097,187 protects VIBERZI and is included in one NDA.

This patent has thirty-one patent family members in twenty countries.

Summary for Patent: 12,097,187

Title:	Opioid receptor modulator dosage formulations
Abstract:	Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6 -dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy -benzoic acid, and processes for the preparation and administration of these formulations.
Inventor(s):	Tim Costello, Leonard Scott Dove, J. Michael Davenport, Gail McIntyre, Paul Covington, David Andrae
Assignee:	Allergan Holdings ULC
Application Number:	US18/324,449
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,097,187
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 12,097,187

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-001	May 27, 2015		RX	Yes	No						REDUCTION OF THE FREQUENCY OF ABDOMINAL PAIN AND DIARRHEA, IN AN INFLAMMATORY BOWEL DISEASE WITH DIARRHEA (IBS-D) PATIENT, WITH ELUXADOLINE TWICE DAILY WITH FOOD

International Family Members for US Patent 12,097,187

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014241076
Brazil	112015022753
Canada	2906472
Canada	3254178
China	105228629
China	110917159